

**In the claims:**

Please amend the claims as follows:

1. **(Currently Amended)** A non-photoreactive targeted oligonucleotide construct comprising: a targeting moiety which localizes to a site in an organism; an oligonucleotide complementary to a nucleic acid of interest; and a detectable label, wherein said construct is not encapsulated in a liposome or linked to a lipid and wherein said construct does not comprise a receptor-binding internalized ligand.
2. **(Original)** A targeted oligonucleotide construct as in claim 1, wherein the targeting moiety is selected from a lipid, an antibody, a lectin, a ligand, a sugar, a steroid, a hormone, a nutrient, and a protein.
3. **(Original)** A targeted oligonucleotide construct as in claim 1, wherein the detectable label is selected from a chemiluminescent label, a radioisotope, a fluorescent label, a paramagnetic contrast agent, and a metal chelate.
4. **(Previously Presented)** A targeted oligonucleotide construct as in claim 1, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is modified to enhance its efficacy, pharmacokinetic properties, or physical properties.
5. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein the detectable label and the targeting moiety are each coupled to the oligonucleotide in any configuration that maintains the desired activity of said label and said moiety.
6. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein the oligonucleotide and the detectable label are each coupled to the targeting moiety in any configuration that maintains the desired activity of said label and said moiety.
7. **(Currently Amended)** A targeted oligonucleotide construct as in claim 1, wherein the targeting moiety and the oligonucleotide are each coupled to the detectable label in any configuration that maintains the desired activity of said label and said moiety.
8. **(Currently Amended)** A non-photoreactive targeted oligonucleotide conjugate comprising: a targeting moiety which localizes to a site in an organism; an

oligonucleotide complementary to a nucleic acid of interest, and a therapeutic agent, wherein said construct is not encapsulated in a liposome or linked to a lipid and wherein said construct does not comprise a receptor-binding internalized ligand.

9. **(Original)** A targeted oligonucleotide construct as in claim 8, wherein the targeting moiety is selected from a lipid, an antibody, a lectin, a ligand, a sugar, a steroid, a hormone, a nutrient, and a protein.
10. **(Original)** A targeted oligonucleotide construct as in claim 8, wherein the therapeutic agent is selected from an enzyme, an enzyme inhibitor, a receptor ligand, a radioisotope, an antibiotic, a steroid, a hormone, a polypeptide, a glycopeptide, a phospholipid, and a drug.
11. **(Previously Presented)** A targeted oligonucleotide construct as in claim 8, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is modified to enhance its efficacy, pharmacokinetic properties, or physical properties.
12. **(Currently Amended)** A targeted oligonucleotide construct as in claim 8, wherein the therapeutic agent and the targeting moiety are each coupled to the oligonucleotide in any configuration that maintains the desired activity of said label and said moiety.
13. **(Currently Amended)** A targeted oligonucleotide construct as in claim 8, wherein the oligonucleotide and the therapeutic agent are each coupled to the targeting moiety in any configuration that maintains the desired activity of said label and said moiety.
14. **(Currently Amended)** A targeted oligonucleotide construct as in claim 8, wherein the targeting moiety and the oligonucleotide are each coupled to the therapeutic agent in any configuration that maintains the desired activity of said label and said moiety.

Claims 15-24 **(Cancelled)**

25. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog that is selected from the group consisting of: an antisense oligonucleotide that is modified with a

cell uptake facilitating moiety, an antisense oligonucleotide that is modified with a stabilizing moiety, an antisense oligonucleotide that is modified to enhance its solubility, and an antisense oligonucleotide that is modified to enhance its resistance to nuclease digestion.

26. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a moiety selected from the group consisting of: biotin, amino glycoside, lipophilic, phosphorothioate, morpholino and deoxy.
27. **(Currently Amended)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a phosphorothioate moiety.
28. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to mRNA.
29. **(Previously Presented)** A targeted oligonucleotide construct as in claim 4, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to a gene selected from the group consisting of: C-myc, N-myc, C-myc and PSA gene specific antisense.
30. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog that is selected from the group consisting of: an antisense oligonucleotide that is modified with a cell uptake facilitating moiety, an antisense oligonucleotide that is modified with a stabilizing moiety, an antisense oligonucleotide that is modified to enhance its solubility, and an antisense oligonucleotide that is modified to enhance its resistance to nuclease digestion.
31. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a moiety selected from the group consisting of: biotin, amino glycoside, lipophilic, phosphorothioate, morpholino and deoxy.

32. **(Currently Amended)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide analog derivatized with a phosphorothioate group.
33. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to a gene selected from the group consisting of : C-myb, N-myc, C-myc and PSA gene specific antisense.
34. **(Previously Presented)** A targeted oligonucleotide construct as in claim 11, wherein the oligonucleotide is an antisense oligonucleotide or an antisense oligonucleotide analog that is specific to mRNA.